Establishment and evaluation of a prognostic model for patients with unresectable gastric cancer liver metastases

Figure 1 Flow chart of study.

Figure 2 A nomogram model for predicting 1-, 3- and 5-yr overall survival in patients with Chinese type for gastric cancer liver metastases type III.

Figure 3 Area under the receiver operating curve for development cohort and validation cohort. A-C: Area under the receiver operating curve (AUC) of 1-, 3-, and 5-yr prognostic models for Chinese type for gastric cancer liver metastases (C-GCLM) type III patients in the developed cohort; D-F: AUC of the 1-, 3-, and 5-yr prognostic models of C-GCLM type III patients in the validation cohort.

Figure 4 Calibration curves for development cohort andvalidation cohort. A-C: Calibration curves of 1-, 3-, and 5-yr prognostic models for Chinese type for gastric cancer liver metastases (C-GCLM) type III patients in the development cohort; D-F: Validate the calibration curve of the 1-, 3-, and 5-yr prognostic models for C-GCLM type III patients in the validation cohort.

Figure 5 Decision analysis curves for development cohort and validation cohort. A-C: Decision analysis curves (DAC) of 1-, 3-, and 5-yr prognostic models for Chinese type for gastric cancer liver metastases (C-GCLM) type III patients in the development cohort; D-F: DAC of 1-, 3- and 5-yr prognostic models for C-GCLM type III patients in the validation cohort.

Figure 6 Kaplan-Meier survival curves for each predictor. A: Albumin; B: Extrahepatic metastases; C: Surgery; D: Tumor size; E: Chemotherapy.